Search DIAN Tissue Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-T1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 111 - 112 of 112

Investigator:

Levin / Jucker

Title:

α-Synuclein co-pathology -related patterns in ADAD mutation carriers

Date of Request:

08/16/2024

Status:

pending approval

ID:

DIAN-T2407

Aim 1:

We will investigate differences in the proteinomic profile in RT-QuIC positive mutation carriers compared to RT-QuIC negative carriers (all EYO >0) to determine LB related patterns in the respective datasets.

Aim 2:

We will investigate differences in imaging in RT-QuIC positive mutation carriers compared to RT-QuIC negative carriers (all EYO >0) to determine LB related patterns in the respective datasets.

Aim 3:

We will investigate differences in the clinical data in RT-QuIC positive mutation carriers compared to RT-QuIC negative carriers (all EYO >0) to determine LB related patterns in the respective datasets.

Aim 4:

We will investigate differences in the genetic risk factor profiles (such as ApoE) in RT-QuIC positive mutation carriers compared to RT-QuIC negative carriers (all EYO >0) to determine LB related patterns in the respective datasets.

Investigator:

n/a

Title:

Biogen-DIAN-TU BIIB080 Design

Date of Request:

11/20/2024

Aim 1:

Patient characteristics of preclinical AD with EYO -10 to +10, including (but not limited to): % amyloid positive, baseline characteristics (especially baseline tau PET), rate of change in tau PET and CDR-SB;

Aim 2:

How is tau PET composite derived; If we were to include plasma p-tau enrichment, what would be the threshold?

Aim 3:

Sample size calculation and assumptions for 2 year and 1 year tau PET assessment If we were to combine both DIAN and sporadic AD for this preclinical study, what would be the assumptions and sample size?